Reprieve Cardiovascular™, a newly formed company affiliated with RenalGuard Solutions™, is a pioneering medical device company focused on improving outcomes for patients suffering from acute decompensated heart failure (ADHF). RenalGuard also announced the completion of a $7 million financing provided by strong support from existing investors and Abiomed, Inc. as a participant and strategic lead.
Reprieve Cardiovascular will demonstrate its innovative Guided Diuretic Therapy at the Heart Failure Society of America’s 22nd Annual Scientific Meeting in Nashville, Tennessee, beginning September 15, 2018. The therapy is being investigated as a treatment for patients who are fluid-overloaded due to heart failure, with the potential to speed decongestion while protecting core organ function, shorten hospital stays, and reduce re-hospitalization in ADHF patients.
Initial results from a study demonstrating the feasibility of using Reprieve Cardiovascular’s Guided Diuretic Therapy to optimize fluid management in ADHF patients while alleviating related symptoms were presented at Heart Failure 2018 in May. Reprieve Cardiovascular utilizes the RenalGuard platform, marketed by RenalGuard Solutions™, Inc.
“I have been impressed with the early experience in the EU, led by Prof. Ponikowski in Wroclaw, Poland, for treating patients with acutely decompensated heart failure with the Reprieve Cardiovascular technology,” said Maria R. Costanzo, M.D., a cardiologist at Advocate Good Samaritan Hospital in Downers Grove, IL. “Effective decongestion is critical to the ability to eventually reduce hospital length-of-stay and readmissions. The proposed mechanism of action of Reprieve Cardiovascular’s Guided Diuretic Therapy is based on important physiological principles and can potentially address the problem of fluid overload in many heart failure patients. I am eager to offer this therapy to my patients once the appropriate clinical trials have confirmed its safety and effectiveness.”
“We are thrilled with the initial results from the study that demonstrate a promising step towards a new therapy for patients facing heart failure. Reprieve Cardiovascular’s fluid management technology may precisely enable the controlled decongestive therapy that ADHF patients need,” said Jim Dillon, CEO of Reprieve Cardiovascular. “Our Guided Diuretic Therapy has the potential to establish a new front-line standard of care for heart failure patients, allowing physicians to maximize fluid removal while protecting patients from the potential negative impact of excessive fluid loss when receiving diuretics. At Heart Failure 2018, we experienced overwhelming interest in our Late Breaking Clinical Trial presentation and Satellite Symposium, as well as numerous mentions in Acute Heart Failure presentations. We look forward to a similar response to our demonstration at the HFSA Scientific Meeting in September.”
For more information about Reprieve Cardiovascular and its Guided Diuretic Therapy, HFSA 2018 attendees are encouraged to visit booth 415 in the exhibit hall. The Reprieve technology is available for investigational use only in the United States.